56290-94-9

56290-94-9 structure

Name: 5-[2-[[3-(1,3-benzodioxol-5-yl)-1-methylpropyl]amino]-1-hydroxyethyl]salicylamide
Chemical Name: 5-[2-[4-(1,3-benzodioxol-5-yl)butan-2-ylamino]-1-hydroxyethyl]-2-hydroxybenzamide
CAS Number: 56290-94-9
Molecular Formula: C₂₀H₂₄N₂O₅
Molecular Weight: 372.41500
Catalog: Signaling Pathways GPCR/G Protein Adrenergic Receptor
Create Date: 2018-09-16 17:49:27
Modify Date: 2025-08-25 12:48:23
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1].

Name	5-[2-[4-(1,3-benzodioxol-5-yl)butan-2-ylamino]-1-hydroxyethyl]-2-hydroxybenzamide
Synonyms	RMI 81,968 MEDROXALOL EINECS 260-099-3 Medroxalolum

Description	Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor
In Vitro	Medroxalol (0.1-10 μM; 20 min) shows α- and β-adrenergic receptor antagonism in isolated rabbit aortic strip[1]. Cell Viability Assay[1] Cell Line: Isolated rabbit aortic strip Concentration: 0.1-10 μM Incubation Time: 20 min Result: Showed pA2 values of 6.09 and 7.73 for α-adrenergic receptors and β-adrenergic receptors, respevtively.
In Vivo	Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats[1]. Animal Model: Male spontaneously hypertensive rats (SHR)[1] Dosage: 12.5, 25, or 50 mg/kg Administration: Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days Result: Produced a dose-related fall in blood pressure.

56290-93-8

~84%

56290-94-9

Literature: Grisar; Claxton; Bare; Dage; Cheng; Woodward Journal of Medicinal Chemistry, 1981 , vol. 24, # 3 p. 327 - 336

Precursor 1
56290-93-8
DownStream 0